NewAmsterdam Pharma

1. REMBRANDT FDC readout2026REMBRANDT FDC readout, 2026, notable
2. Ubeslo® / Evlarco® FDC EU2H 2026Ubeslo® / Evlarco® FDC EU, 2H 2026, material
3. RUBENS obicetrapib Ph3 toplineYear-end 2026RUBENS obicetrapib Ph3 topline, Year-end 2026, material
4. PREVAIL obicetrapib interim4Q 2026PREVAIL obicetrapib interim, 4Q 2026, material
5. Ubeslo® / Evlarco® commercial launch4Q 2026Ubeslo® / Evlarco® commercial launch, 4Q 2026, routine
6. PREVAIL obicetrapib readout1Q 2027PREVAIL obicetrapib readout, 1Q 2027, major
7. AZD0780 AstraZeneca topline1H 2027AZD0780 AstraZeneca topline, 1H 2027, material
8. PREVAIL obicetrapib toplineEnd of 2027PREVAIL obicetrapib topline, End of 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.